M&T Bank’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $510K | Sell |
3,872
-446
| -10% | -$59.2K | ﹤0.01% | 1101 |
|
|
2025
Q4 | $613K | Buy |
4,318
+1,007
| +30% | +$146K | ﹤0.01% | 1028 |
|
|
2025
Q3 | $465K | Sell |
3,311
-1,066
| -24% | -$144K | ﹤0.01% | 1013 |
|
|
2025
Q2 | $550K | Buy |
4,377
+139
| +3% | +$15.9K | ﹤0.01% | 1035 |
|
|
2025
Q1 | $469K | Sell |
4,238
-2,740
| -39% | -$347K | ﹤0.01% | 1086 |
|
|
2024
Q4 | $952K | Buy |
6,978
+1,322
| +23% | +$164K | ﹤0.01% | 917 |
|
|
2024
Q3 | $651K | Sell |
5,656
-342
| -6% | -$46.9K | ﹤0.01% | 1065 |
|
|
2024
Q2 | $826K | Sell |
5,998
-189
| -3% | -$25.9K | ﹤0.01% | 923 |
|
|
2024
Q1 | $854K | Sell |
6,187
-597
| -9% | -$81.5K | ﹤0.01% | 927 |
|
|
2023
Q4 | $894K | Sell |
6,784
-443
| -6% | -$51K | ﹤0.01% | 915 |
|
|
2023
Q3 | $814K | Sell |
7,227
-2,768
| -28% | -$291K | ﹤0.01% | 914 |
|
|
2023
Q2 | $943K | Sell |
9,995
-496
| -5% | -$48.5K | ﹤0.01% | 894 |
|
|
2023
Q1 | $1.06M | Sell |
10,491
-1,184
| -10% | -$123K | ﹤0.01% | 843 |
|
|
2022
Q4 | $1.39M | Buy |
11,675
+1,529
| +15% | +$179K | 0.01% | 735 |
|
|
2022
Q3 | $1.08M | Sell |
10,146
-3,953
| -28% | -$401K | ﹤0.01% | 797 |
|
|
2022
Q2 | $294K | Buy |
14,099
+11,456
| +433% | +$1.06M | ﹤0.01% | 1196 |
|
|
2022
Q1 | $248K | Buy |
2,643
+92
| +4% | +$7.8K | ﹤0.01% | 1297 |
|
|
2021
Q4 | $218K | Sell |
2,551
-294
| -10% | -$27K | ﹤0.01% | 1412 |
|
|
2021
Q3 | $274K | Sell |
2,845
-5
| -0.2% | -$472 | ﹤0.01% | 1279 |
|
|
2021
Q2 | $278K | Buy |
2,850
+9
| +0.3% | +$863 | ﹤0.01% | 1296 |
|
|
2021
Q1 | $277K | Sell |
2,841
-163
| -5% | -$17.1K | ﹤0.01% | 1265 |
|
|
2020
Q4 | $289K | Sell |
3,004
-45
| -1% | -$4.35K | ﹤0.01% | 1360 |
|
|
2020
Q3 | $294K | Buy |
3,049
+173
| +6% | +$20K | ﹤0.01% | 1244 |
|
|
2020
Q2 | $351K | Sell |
2,876
-496
| -15% | -$54.8K | ﹤0.01% | 1114 |
|
|
2020
Q1 | $291K | Buy |
3,372
+59
| +2% | +$5.77K | ﹤0.01% | 1144 |
|
|
2019
Q4 | $355K | Sell |
3,313
-168
| -5% | -$17.6K | ﹤0.01% | 999 |
|
|
2019
Q3 | $313K | Buy |
3,481
+104
| +3% | +$9.72K | ﹤0.01% | 1172 |
|
|
2019
Q2 | $286K | Buy |
3,377
+153
| +5% | +$12.6K | ﹤0.01% | 1255 |
|
|
2019
Q1 | $285K | Buy |
3,224
+232
| +8% | +$19.4K | ﹤0.01% | 1233 |
|
|
2018
Q4 | $214K | Sell |
2,992
-95
| -3% | -$9.1K | ﹤0.01% | 1268 |
|
|
2018
Q3 | $380K | Buy |
3,087
+248
| +9% | +$28.1K | ﹤0.01% | 1124 |
|
|
2018
Q2 | $278K | Buy |
2,839
+13
| +0.5% | +$1.16K | ﹤0.01% | 1258 |
|
|
2018
Q1 | $235K | Buy |
2,826
+219
| +8% | +$18.5K | ﹤0.01% | 1348 |
|
|
2017
Q4 | $202K | Buy |
+2,607
| New | +$178K | ﹤0.01% | 1429 |
|
|
2016
Q4 | – | Sell |
-7,069
| Closed | -$358K | – | 1740 |
|
|
2016
Q3 | $358K | Buy |
7,069
+2,458
| +53% | +$122K | ﹤0.01% | 1193 |
|
|
2016
Q2 | $210K | Sell |
4,611
-2,042
| -31% | -$94K | ﹤0.01% | 1437 |
|
|
2016
Q1 | $262K | Buy |
+6,653
| New | +$264K | ﹤0.01% | 1343 |
|
|
2015
Q3 | – | Sell |
-6,555
| Closed | -$312K | – | 1938 |
|
|
2015
Q2 | $312K | Sell |
6,555
-219
| -3% | -$9.29K | ﹤0.01% | 1461 |
|
|
2015
Q1 | $269K | Buy |
+6,774
| New | +$242K | ﹤0.01% | 1527 |
|
|
2014
Q2 | – | Sell |
-61
| Closed | -$1K | – | 1133 |
|
|
2014
Q1 | $1K | Buy |
+61
| New | +$1.04K | ﹤0.01% | 1186 |
|
Other funds holding NBIX
VPM
VCM
M&T Bank's NBIX Position: Q1 2026 in Review
M&T Bank reduced its Neurocrine Biosciences (NBIX) stake by 10% in Q1 2026, selling an estimated $59.2K and leaving 3,872 shares worth $510K. The position accounts for ﹤0.01% of the portfolio, ranked #1101.
M&T Bank first reported a position in NBIX in Q1 2014 and has held it in 40 quarters since. The position peaked at $1.39M in Q4 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- M&T Bank held 3,872 shares of Neurocrine Biosciences worth $510K as of Q1 2026.
- M&T Bank sold 446 Neurocrine Biosciences shares in Q1 2026, an estimated $59.2K.
- Neurocrine Biosciences made up ﹤0.01% of M&T Bank's portfolio in Q1 2026, its #1101 holding.
- M&T Bank first reported a position in Neurocrine Biosciences in Q1 2014 and has held it in 40 quarters since.
- M&T Bank's Neurocrine Biosciences position peaked at $1.39M in Q4 2022.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on M&T Bank's 13F filing for Q1 2026, filed 12 May 2026.